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Abstract
Although midazolam is a frequently used sedative in neonatal intensive care units, its use in preterm neonates has been off-label. Recently, a new
dosing advice for midazolam for sedation on intensive care units has been included in the label (0.03 mg/[kg·h] for preterm neonates <32 weeks and
0.06 mg/[kg·h] for neonates >32 weeks). Concentration-time data of a prospective multicenter study (29 patients,median gestational age 26.7 [range
24.0-31.1 weeks]) were combined with previously published data (26 patients, median gestational age 28.1 [range 26.3-33.6 weeks]), and a population
pharmacokinetic model describing the maturation of midazolam pharmacokinetics was developed in NONMEM 7.3. Clearance was 73.7 mL/h for a
neonate weighing 1.1 kg and changed nonlinearly with body weight (exponent 1.69). Volume of distribution increased linearly with body weight and
was 1.03 L for a neonate weighing 1.1 kg. Simulations of the newly registered dosing show considerable differences in steady-state concentrations in
preterm neonates. To reach similar steady-state concentrations of 400 µg/mL (±100 µg/mL), a dose of 0.03 mg/(kg·h) is adequate for neonates 1 kg
and 2 kg but would have to be reduced to 0.02 mg/(kg·h) (−33%) in neonates <1 kg and increased to 0.04 mg/(kg·h) (+33%) in neonates weighing
>2 kg and 2.5 kg. The impact of the observed differences in exposure is difficult to assess because no target concentrations have yet been defined
for midazolam, but the current analysis shows that one should be cautious in giving dosage advice based on historical data with a lack of reliable
pharmacokinetic and effect data.
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Midazolam is 1 of the most frequently used sedatives
in neonatal intensive care units,1,2 and its use keeps
on increasing.3 Besides acting as a sedative-hypnotic,
midazolam is also used for the treatment of refractory
seizures and less-frequently for anesthesia.1 Data on
the pharmacodynamics of midazolam are very scarce.
Jacqz-Aigrain et al,4 Anand et al,5 andArya andRamji6
studied the sedative effect of midazolam in placebo-
controlled trials and concluded that it was superior
to placebo. A recent meta-analysis of these 3 studies
points out the risk of potential severe side effects associ-
ated with the use of midazolam.3 In particular, Ng et al.
report a higher incidence of adverse neurological events
at 28 days postnatal age when midazolam is compared
with morphine as observed in the study performed by
Anand.5 This highlights that more research is urgently
needed.
Concerning the pharmacokinetics of midazolam, an
influence of maturation in preterm neonates is likely, as
midazolam is mainly metabolized by CYP3A.7 CYP3A
activity is known to be very low directly after birth
and to increase rapidly during the first weeks of life,
reaching values comparable to those in adults around
the age of 1 year.8,9 In accordance with this, the
lowest clearance values have been reported in preterm
neonates,10,11 and these increase with age.12–15 In ad-
dition to the influence of maturational status, severity
of disease and inflammation may affect midazolam
elimination in critically ill neonates and children.16,17
No target concentration for the use of midazolam in
preterm neonates has been defined because quantifying
the relationship between plasma concentration and
sedative effect has been difficult.18
Until recently, the use of midazolam in preterm
neonates was off-label because dosing information in
this vulnerable population was lacking in the Summary
of Product Characteristics.1,3 Based on a review of
the published literature, the drug label has recently
been changed, and new dosing advice for midazolam
sedation in preterm neonates treated in intensive care
units has been included in the label. In the current
label, for neonates with a gestational age of less than
32 weeks, lower infusion rates of 0.03 mg/(kg·h) are
suggested, as compared with neonates with gestational
ages above 32 weeks for whom 0.06 mg/(kg·h) is
proposed.
In the current study we analyzed the midazolam
concentration-time data of a prospective multicenter
study carried out in 4 neonatal intensive care units in
the Netherlands. We have combined those data with the
data on intravenous administration of midazolam in
preterm neonates published earlier by de Wildt et al19
to develop a population pharmacokinetic model that
describes the maturation of midazolam pharmacoki-
netics in preterm infants. Finally, we used this model
to evaluate the performance of the newly registered
midazolam dosing for preterm neonates.
Methods
Data and Studies
The Erasmus Medical Center ethics review board
approved the protocols, and written informed consent
from parents/legal guardians was obtained before
study initiation. The Drug dosage Improvement
NeOnates (DINO) study (study 1, MEC-2014-067,
NL47409.078.14, ClinicalTrials.gov NCT02421068)
prospectively studied a total of 9 drugs, including
midazolam, routinely used in preterm infants
born before 32 weeks of gestation. The primary
objective was to develop pharmacokinetic and
pharmacodynamic models from which evidence-based
individualized dosing regimens can be derived. From
September 2014 to September 2017, 60 midazolam
blood samples from 29 children (13 female, 16 male)
were collected after intravenous administration in 4
participating Dutch level III neonatal intensive care
units (Radboud University Medical Center Nijmegen,
Maastricht University Medical Center Maastricht,
Ma´xima Medical Center Veldhoven, and Sophia
Children’s Hospital Rotterdam). The study made use
of sparse opportunistic sampling to reduce the burden
on the individual child while the dose was determined
by the treating physician. The indication for midazolam
was either a stressful procedure or continuous sedation,
and bolus doses as well as continuous infusions were
administered (Table 1). Additional data (study 2,MEC-
171.586/1998/125) after intravenous administration
were available from a previously published data set
from the neonatal intensive care unit of the Sophia
Children’s Hospital in Rotterdam.19 This data set
contained 172 samples from 26 neonates (16 female,
10 male) (Table 1) obtained 0.5, 1, 2, 4, 6, 12, and
24 hours after a single intravenous dose of 0.1 mg/kg
over 30 minutes for stressful procedures. The combined
data set thus consisted of 232 samples from 55 patients
after intravenous administration for various doses and
indications (Table 1).
Analytic Methods
The plasma concentrations of the de Wildt et al19 data
set were analyzed using gas chromatography with mass
spectrometric detection. The lower limit of quantifica-
tion was 1 µg/L. All samples were analyzed in duplicate,
and the resultant mean concentration was used in the
pharmacokinetic analysis. For further detail on the
analytic method, the reader is referred to the original
publication.19
Within the DINO study midazolam plasma samples
were analyzed using liquid chromatography–tandem
mass spectroscopy with electrospray ionization in the
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Table 1. Patient Characteristics of the DINO Study Data Set (Study 1) and the Shared Data Set (Study 2)
DINO Study Data (Study 1) de Wildt et al19 (Study 2) Combined Data Set
Patients 29 26 55
Samples (samples per neonate) 60 (2.1) 172 (6.6) 232 (4.9)
Doses (doses per neonate) 123 (4.2) 26 (1) 149 (2.7)
Doses for stressful procedures (infusion duration 30 min) 59 (2.0) 26 (1) 85 (1.5)
Doses for continuous sedation (infusion duration >30 min) 65 (2.2) 0 (0) 65 (1.2)
Female neonates, N (%) 13 (45%) 16 (62%) 29 (53%)
Gestational age, wka 26.7 (24.0–31.1) 28.1 (26.3–33.6) 27.3 (24.0–33.6)
Birth weight, kg29,a 0.84 (0.47–1.8) 1.1 (0.75–1.6) 0.95 (0.47–1.8)
Postnatal age (at day of inclusion), da 18 (1–88) 5.5 (3–11) 9 (1–88)
Actual body weight, kg29,a 1.3 (0.6–4.3) 1.0 (0.77–1.6) 1.1 (0.6–4.3)
aData provided as medians and ranges.
positive ionization mode. The lower limit of quantifica-
tion for midazolam was 4 µg/L.20
Population Pharmacokinetic Analysis and Model
Evaluation
The population pharmacokinetic analysis was
performed using NONMEM version 7.3 (ICON
Development Solutions, Ellicott City, Maryland),
supported by Perl-speaks-NONMEM version 3.4.2
and Xpose version 4.3.5.21 Model development was
performed in 4 steps: (1) selection of a structural
model, (2) selection of an error model, (3) covariate
analysis, and (4) internal validation of the model.
The first-order conditional estimation with interaction
method was used throughout model development.
In case of missing covariate information, the last
value observed in the subject was carried forward. For
body weight, linear interpolation between available
measurements was performed. The objective function
value (OFV) was used to compare models, in which a
lower OFV indicated a better fit of the model to the
data. A drop in OFV of more than 3.8 was considered
statistically significant (P < .05) for structural model
selection. Standard errors obtained from NONMEM
and the confidence intervals of the bootstrap analysis
in Perl-speaks-NONMEM (n = 1000) were used to
evaluate the precision of the estimated parameters.
The covariates birth weight, actual body weight at
each day in the neonatal intensive care units, gesta-
tional age, postnatal age, postmenstrual age (calculated
using gestational age and postnatal age), and gender
were evaluated using a stepwise covariate modeling
procedure.22 For the covariate analysis, a significance
level of P  .01 was used for the forward inclusion
and a significance level of .001 for the backward
elimination.
Key models as well as the final model were evaluated
using goodness-of-fit plots and normalized prediction
distribution errors23 based on 1000 simulations of the
model and a bootstrap analysis based on 1000 samples
of the data.
Evaluation of the Recently Registered Dosing Regimen
With use of the final model, 1000 simulations of the
newly proposed dosing regimen were performed for 9
hypothetical preterm neonates weighing 0.5, 0.75, 1,
1.25, 1.5, 1.75, 2, 2.25, or 2.5 kg. A continuous infusion
of 0.03 mg/(kg·h) was administered over a duration of
72 hours as proposed by the label for preterm infants
with a gestational age of less than 32 weeks. Steady-
state concentrations were evaluated for their ability to
achieve the indicative target concentration of 400 µg/L
as proposed by Ahsman et al24 while allowing for
10% (360-440 µg/L) and 25% (300-500 µg/L) variation
in the population-predicted steady-state concentration,
respectively.
Results
Population Pharmacokinetic Analysis and Model
Evaluation
A 1-compartment model described the available data
best. Clearance was best predicted by actual body
weight using a power function (P< .001; –116 points in
OFV). Body weight was also identified as best predictor
for volume of distribution (P< .01;−9 points in OFV).
Because the estimated exponent for volume was close
to 1, a linear influence of body weight on volume of
distribution was tested for comparison. This led to
an equally good fit (+0.2 points in OFV) and was
therefore carried forward. No other covariates were
found. More details on the covariate analysis can be
found in Supplemental Table S1.
Figure 1 shows how clearance was found to change
with body weight. The individual post hoc clearance
estimates (black dots) are spread evenly around the
population value for clearance (black line).
The parameter estimates and their respective boot-
strap estimates are provided in Table 2. Figure 2 shows
the goodness-of-fit plots of the final model. Model
evaluation showed no trends toward a model misspeci-
fication and no other remaining trends with respect to
time, concentration, and gestational age. An absence
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Figure 1. Clearance vs body weight function for the final model: the black line represents the population value for clearance according to the model;
the black dots represent the individual post hoc clearance estimates.
Table 2. Parameter Estimates of the Final Model and Their Correspond-
ing Bootstrap Estimates
Parameter
Final Model
Estimate (RSE%)
[Shrinkage]
Bootstrap Estimate
(95%CI)
Fixed effects
CL [L/h] = CLp 0.0737 (13%) 0.0787 (0.0550–0.102)
CLi = CLp × (WTi/Median
WT)ƟWT
ƟWT 1.69 (10%) 1.67 (0.406–2.47)
V [L] = Vp
Vi = Vp × (WTi/Median
WT)
1.03 (21%) 1.11 (0.877–1.37)
Interindividual variability (η)
On CL [%] 91.9 (15%) [8%] 96.6 (67.5–128)
On V [%] 67.2 (16%) [17%] 72.7 (47.4–96.8)
Residual variability
Proportional (%) 33.8 (16%) 34.0 (28.6–39.4)
Additive (µg/L) 0.218 (56%) 0.283 (0.0800–0.585)
CL indicates clearance; i, individual; p, population mean value of a parameter
for an individual with body weight of 1.12 kg; RSE, residual standard error;
V, central volume of distribution; WT, actual body weight (median WT =
1.12 kg);ƟWT, exponent for influence of WT on CL .
Bootstrap convergence rate was 83.1%.
of trends in the individual deviation of clearance and
volume of distribution (η) versus covariate plots shows
that covariates have been successfully implemented
(Supplemental Figure S1). The normalized prediction
distribution error shows that the variability in the
observed data has been adequately described (Supple-
mental Figure S2).
Evaluation of the Recently Registered Dosing Regimen
Figure 3A illustrates concentration-time profiles of
preterm infants with different body weights when dosed
according to the new dosing regimen (0.03mg/[kg·h] for
72 hours). The dashed line represents a target concen-
tration of 400 µg/L. The plots show that midazolam
plasma concentrations in children with lower body
weights are higher than those of children with higher
body weights (Figure 3A). Seventy-two hours after
start of therapy the mean concentration was predicted
to be 754 µg/L, 421 µg/L, and 262 µg/L for preterm
infants with body weights of 0.5, 1.25, and 2.5 kg,
respectively. At this time point 27.8%, 10.6%, and 5.4%
of the individual simulated concentrations were above
1000 µg/L, and 5.7%, 19.6%, and 37.6% were below
200 µg/L, for a preterm infant weighing 0.5 kg, 1.25 kg,
and 2.5 kg, respectively. This added up to a total of
11.6% and 23.2% of all simulated concentrations above
1000 µg/L and below 200 µg/L, respectively, from all
simulations. Moreover, the time to reach steady state
differed for different bodyweights.Whereas steady state
is reached after 24 hours in neonates weighing 2 kg or
more, it takes more than 48 hours in children weighing
1 kg or less and between 24 and 48 hours in children
between 1 and 2 kg (Figure 3A).
The model predicts that a median steady-state con-
centration of 400 µg/L (±10%) can be achieved by
reducing the dose by 50% from 0.03 mg/(kg·h) to
0.015 mg/(kg·h) in preterm neonates weighing 0.5 kg,
by 33% to 0.02 mg/(kg·h) in neonates weighing 0.75 kg,
and to 0.024 mg/(kg·h) in neonates weighing 1 kg
(Figure 3B). For preterm infants with a body weight
of 1.25 kg or 1.5 kg, the proposed dose would be
adequate. In preterm infants with a body weight of
1.75 kg, a dose increase of 20% (0.036 mg/kg) was
suitable, whereas in neonates weighing 2 to 2.25 kg the
dose had to be increased by 33% (0.04mg/[kg·h]) and by
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Figure 2. Goodness-of-fit plots for the final model. Top, population-predicted (left) and individual predicted (right) concentrations vs observed values
on a log scale. Bottom, conditional weighted residuals (CWRES) vs time on study (left) and gestational age (right).
50% in a childweighing 2.5 kg (Figure 3B). If onewould
consider a target range between 300 µg/L and 500 µg/L
(400 µg/L± 25%) as adequate, a dose of 0.03 mg/(kg·h)
would be adequate in neonates between 1 and 2 kg.
This dose would have to be reduced by one third
(0.02 mg/[kg·h]) in children below 1 kg and increased
by one third in children weighing more than 2 kg and
less or equal to 2.5 kg (0.04 mg/[kg·h], data not shown).
Discussion
In this study we successfully developed a population
pharmacokinetic model for midazolam in preterm
neonates with a gestational age of 24-33 weeks on the
basis of previously published data19 and newly available
data from the prospective multicenter DINO study.
The results of this study show that clearance nonlin-
early increases with body weight (Figure 1), whereas
central volume of distribution linearly increases with
body weight (Table 2). Only due to the utilization of
data from different sources was it possible to develop
a population pharmacokinetic model of this drug.
Although the data of de Wildt et al were very densely
sampled, they only contained data on 1 intravenous
bolus administration per patient.19 The DINO data
made use of sparse opportunistic sampling, which
allowed for the collection of the most informative
data while putting the least burden on this vulnerable
population. This practice resulted in a very low number
of observations per administration, but patients were
followed over a long period of time (up to 30 days)
and received intravenous bolus administrations, con-
tinuous intravenous infusions, or both (Table 1). The
combined data set thus contains sufficient information
to describe the whole postnatal and gestational age
range of preterm neonates, which can support identi-
fying maturational processes and eventually aids dose
finding.
So far, to our knowledge, only 2 population phar-
macokinetic models including preterm neonates have
been published. In 1994 Burtin et al10 studied 187
critically ill neonates with a gestational age of 26 to
42weeks, a birthweight of 700 to 5200 g and a postnatal
age of 0 to 10 days and found that clearance and
Vo¨ller et al 1305
Figure 3. Population-predicted midazolam concentration-time profiles over 72 hours for preterm infants with body weights of 0.5 kg, 0.75 kg, 1 kg,
1.25 kg, 1.5 kg, 1.75 kg, 2 kg, 2.25 kg, and 2.5 kg; dashed lines represent indicative target concentration proposed by Ahsman et al24 for (A) a dose of
0.03 mg/(kg·h) according to the current label and (B) an adjusted dosing regimen to reach a concentration of 400 µg/L at 72 hours postdose.
volume of distribution were directly proportional to
birth weight. They also found a categorical influence
of gestational age, with children with a gestational age
of 39 weeks or older having 1.6 times higher clearance
values. In our analysis we did not find an additional
influence of gestational or postnatal age after body
weight was implemented, which may be explained by
the correlation between age andweight and the fact that
the range in gestational age was low in our data set.
In 1999 Lee et al11 analyzed data of 60 mechanically
ventilated preterm neonates with a gestational age of
24 to 31 weeks, a birth weight of 523 to 1470 g,
and a postnatal age of 2 to 15 days. They found that
clearance and volume of distribution were significantly
lower in infants with a birth weight below 1 kg. We
compared the 2 clearance × weight functions described
in these publicationswith the function that we identified
(Figure 4). Because the data of Burtin et al10 mainly
included infants during the first week of life and the
population of Lee et al had a median postnatal age of
4.5 days,11 we assumed that the current body weight
was approximately equal to birth weight, as preterm
infants do not gain weight during the first 10 days
of life.25 This made us able to depict all clearance
maturation functions in 1 figure, which shows that
the estimates of previous population pharmacokinetic
studies were in close agreement with our results. This
is also true for the clearance estimate in the original
publication of the de Wildt data, which was obtained
using standard noncompartmental techniques.19 On
the basis of these results and the successful model
evaluation, the developed model is suitable for the data
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Figure 4. Comparison of clearance vs weight of the current analysis with literature; the red line represents the function of the current model; the
solid black line represents the clearance estimates of Lee et al11; the dotted line represents the clearance estimates of de Wildt et al19; the dashed
line represents the clearance estimates of Burtin et al.10 All estimates are displayed for the population ranges included in the respective studies only.
used (Table 2, Figure 2, Supplemental Figure S1) but
should also be suitable to describe intravenous data
from other preterm neonatal populations. The fact that
body weight and not gestational age or birth weight was
the best covariate to describe the data in our model is
most likely related to the broader range in postnatal
age and the longer observation period, resulting in
body weight undergoing significant changes over time.
With the low postnatal age range in the 2 previous
studies,10,11 it might have been difficult to detect an
influence of postnatal maturation. Previous studies in
older children have shown that clearancemight be lower
in childrenwith systemic inflammation.16,17 Because the
data set of de Wildt et al did not contain information
on inflammation, and C-reactive protein values have
been infrequently sampled in the DINO population,19
we were not able to test this covariate, but it seems
possible that itmight be able to explain some of the high
interindividual variability in clearance.
One of themajor advantages of population pharma-
cokineticmodeling is that it offers the possibility of per-
forming simulations based on the developed model.26
In this case we were able to review the recently proposed
dosage advice for midazolam in preterm neonates. Our
results show that when 1 fixed body weight–based dose
is used for all preterm neonates up to 32 weeks of gesta-
tion, and another for preterm neonates above 32 weeks
of gestation, steady-state concentrations differ consid-
erably. The steady-state concentration after a 72-hour
infusion of 0.03mg/(kg·h) was nearly 3 times as high for
a child of 0.5 kg when compared with a child weighing
2.5 kg (754 vs 262 µg/L). Moreover, when performing
our analysis, wewere facedwith the problemof defining
the cutoff between the dosage advised below 32 weeks
and that for above 32 weeks. We could not determine
for how long after birth the dosage advice should be
applicable. For example, if a child is born at 30 weeks
of gestation and weighs 1.5 kg, should the dosage
be changed from 0.03 mg/(kg·h) to 0.06 mg/(kg·h) if
the child is 2 weeks old (postmenstrual age 32 weeks)
and weighs 1.8 kg. Our developed model would not
support such a sharp cutoff, because clearance increases
gradually with body weight (Figure 3A). Also, the
newly registered dosage does not give advice on suitable
loading doses.With regard to the considerably long and
weight-dependent time to reach steady state, this seems
desirable (Figure 3A).
No target concentration for the use of midazolam in
preterm neonates has been defined as quantifying the
relationship between plasma concentration and seda-
tive effect. One publication related COMFORT scores
to midazolam concentrations but did not find a signif-
icant correlation. In addition, the authors concluded
that comediation might be of considerable influence
to this relationship.18 Nevertheless, different authors
have attempted to define indicative target concentra-
tions. Jacqz-Aigrain et al4 calculated their midazolam
doses to obtain plasma concentrations between 200 and
1000 µg/L but without directly relating this target range
to a specific effect. Although substantial variability was
observed, only 2 of 46 infants with a gestational age of
less than 32 weeks had a value above 1000 µg/L, and
none had a value below 200 µg/L. The dosing schedule
they used in this study was 0.06 mg/(kg·h) during the
first 24 hours in all neonates and a dose reduction
to 0.03 mg/(kg·h) from 24 hours onward in neonates
younger than 33 weeks. Again, no correlation between
sedation score and midazolam concentrations could be
Vo¨ller et al 1307
found. Ahsman et al proposed a target concentration
of 400 µg/L for continuous infusions in term neonates
because this was the median plasma concentration
observed in their study. They did, however, assume
that all of the patients included had been successfully
titrated to their target sedation.24 To date, no clear
concentration-effect relationship for midazolam can
be found; it is difficult to assess the impact of the
observed differences. If we can assume a very broad
target range of 200-1000 µg/L, 65.2% of the simulated
infants treated with the newly registered dosing regimen
would be within this therapeutic window. Part of the
reason for the rather large proportion of treated infants
outside the therapeutic window is the large interindi-
vidual variability observed in the studied population,
which has also been observed in the 2 other population
pharmacokinetic models developed up to now.10,11 This
large unexplained interindividual variability may partly
be caused by the use of 2 assays for quantification
of midazolam and the limited (additional) covariate
data available in our study, which did not enable us to
study potentially interesting factors such as interacting
comedication, ethnicity, severity of disease, and inflam-
mation. Inflammation and disease severity have been
reported to affect midazolam elimination in critically ill
neonates and children16,17 and thus may explain some
of the variability. However, because the data set of
de Wildt et al did not contain information on inflam-
mation, and because C-reactive peptide values have
been infrequently sampled in the DINO population,19
we were not able to test this covariate. Physiologically
based PK modeling, which can incorporate variation
in CYP3A4 activity as a function of maturation or
inflammation, can be used for simulations of the conse-
quences of these variables. This approach has been used
in pediatric PK assessments, including midazolam.27
When aiming for a comparable exposure in all
preterm infants, the dosage of 0.03 mg/kg/h would
have to be reduced in children weighing 1 kg or less
and would have to be increased in children weighing
1.75 kg or more (Figure 3B). For a median child born
at 33 weeks of gestation weighing around 2 kg,28 we
would recommend an increase in dose by 33%, thus to
0.04 mg/kg/h and not to 0.06 mg/kg/h. The proposed
dosing regimen could not be evaluated beyond a gesta-
tional age of 34 weeks because the population did not
include individuals above that gestational age.
Conclusion
In conclusion, the newly registered dosage advice does
not lead to uniform exposure in preterm infants re-
sulting in considerable differences in typical steady-
state concentrations and time to reach steady-state.
The impact of this is difficult to assess, as no target
concentrations have yet been defined for midazolam,
but the current analysis shows that one should be
cautious in giving dosage advice based on historical
data with a lack of reliable pharmacokinetic and effect
data.
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